A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150

Annals of Oncology

Volumn 18, Issue 1, 2007, Pages 116-121

  Belch, A ^a   Kouroukis, C T ^b   Crump, M ^c   Sehn, L ^d   Gascoyne, R D ^d   Klasa, R ^d   Powers, J ^e   Wright, J ^f   Eisenhauer, E A ^e  

^a CROSS CANCER INSTITUTE   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Mantle cell lymphoma

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; LOPERAMIDE; NSC 681239; RITUXIMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AMNESIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BIOCHEMISTRY; BLOOD TOXICITY; BOLUS INJECTION; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FLUID RETENTION; GRANULOCYTE; HUMAN; HYPONATREMIA; INFECTION; LUNG CONGESTION; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROMUSCULAR DISEASE; NEUROPATHIC PAIN; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SOMATOSENSORY DISORDER; SPEECH DISORDER; THROMBOCYTE; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRAZINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846530661     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl316     Document Type: Article

References (18)

1. Banks PM, Chan J, Cleary M et al. Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992; 16: 637-640.
2. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification for non-Hodgkin's lymphoma. Blood 1997; 89: 3909-3918.
3. Weisenburger D, Vose J, Greiner T et al. Mantle cell lymphoma: A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64: 190-196.
4. Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes_European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13: 2819-2826.
5. Fisher RI, Dahlbert S, Nathwani BN et al. A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma. A Southwest Oncology Group Study. Blood 1995; 85: 1075-1082.
6. Argatoff LH, Connors JM, Klasa RJ et al. Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 1997; 89: 2067-2078.
7. Rosenberg CL, Wong E, Petty EM et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991; 88: 9638-9642.
8. Pham LV, Tamayo AT, Yoshimura LC et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
9. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
10. Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420-4427.
11. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
12. Richardson PG, Sonneveld P. Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
13. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
14. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
15. National Institute of Health. NCI: Common Toxicity Criteria, Version 2.0; http://ctep.info.nih.gov/reporting/ctc.html (Accessed 22 August 2006).
16. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
17. Goy A, Younes A, McLaughlin P et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 657-658.
18. O'Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 657-658.